

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Beni Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811541542

Date: 29th May, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcomes of Board Meeting

1. **Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Audited Financial Results and Independent Auditor's Report for the quarter and year ended 31.03.2022**
2. **Appointment of M/s SBR & Co. LLP, Company Secretaries, New Delhi as Secretarial Auditors of the Company for the Financial Year 2021-22**
3. **Appointment of M/s SBR & Co. LLP, Company Secretaries, New Delhi to issue Annual Secretarial Compliance Report for the Financial Year 2021-22 as per Regulation 24A of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

We refer to our letter dated 20 May, 2022 intimating about the meeting of the Board of Directors of the Company ("the Board") scheduled to be held on Saturday, 28 May, 2022 inter-alia to consider, approve and take on record the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31 March, 2022.

Further, please refer to our letter dated 28 May, 2022 regarding adjournment of Board Meeting scheduled to be held on Saturday, 28 May, 2022, till Sunday 29 May, 2022 to consider the remaining agenda including consideration and approval of financial results for the aforesaid period.

We would like to inform you that the Board at its' adjourned meeting held today i.e. on 29 May 2022, inter-alia has considered and approved the Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2022 of the Company as per Indian Accounting Standards (IND-AS) along with the Independent Auditor's Report. Copy of the results along with the Independent Auditor's Report of Statutory Auditors is attached herewith for your perusal.

Further the Board of Directors of the Company has considered and approved the following also:

1. **Appointment of M/s SBR & Co. LLP, Company Secretaries, New Delhi as Secretarial Auditors of the Company for the Financial Year 2021-22 (Brief Profile is attached herewith)**
2. **Appointment of M/s SBR & Co. LLP, Company Secretaries, New Delhi to issue Annual Secretarial Compliance Report for the Financial Year 2021-22 as per Regulation 24A of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Brief Profile is attached herewith)**

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 28/05/2022 at 11:45 A.M. and concluded at 29/05/2022 at 09:20 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Hanuman Prasad
Company Secretary & Compliance Officer
M.No.: 46027

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2022

In Rs.

Sr. No.	Particular	For the quarter ended			For the year ended	
		31-Mar-22 Audited	31-Dec-21 Un-Audited	31-Mar-21 Audited	31-Mar-22 Audited	31-Mar-21 Audited
I	Revenue From Operations	-	2,46,240	2,16,895	7,05,640	20,80,805
II	Other Income	55,522	7,84,548	29,221	8,40,070	29,221
III	Total Revenue (I+II)	55,522	10,30,788	2,46,116	15,45,710	21,10,026
IV	Expenses					
	Cost of materials consumed	-	15,410	17,100	19,410	50,242
	Purchases of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	7,65,600
	Employee benefits expense	8,42,081	1,33,250	1,56,300	13,98,781	8,57,734
	Financial costs	-	-	17,74,570	4,26,203	17,74,570
	Depreciation and amortization expense	-4,99,841	4,00,238	4,47,806	8,40,873	18,92,123
	Other expenses	23,70,645	3,73,393	11,13,716	30,68,718	17,87,900
	Total Expenses (IV)	27,12,885	9,22,291	35,09,492	57,53,985	71,28,169
V	Profit / (Loss) before exceptional item and tax (III-IV)	-26,57,363	1,08,497	-32,63,376	-42,08,275	-50,18,143
VI	Exceptional Item	41,91,783	-	-	41,91,783	-
VII	Profit/loss before Tax (V-VI)	15,34,421	1,08,497	-32,63,376	-16,492	-50,18,143
VIII	Tax expenses					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	76,910	-	5,72,371	76,910	5,72,371
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	14,57,511	1,08,497	-38,35,747	-93,402	-55,90,514
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	14,57,511	1,08,497	-38,35,747	-93,402	-55,90,514
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	14,57,511	1,08,497	-38,35,747	-93,402	-55,90,514
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):					
	1) Basic	0.48	0.04	-1.26	-0.03	-1.83
	2) Diluted	0.48	0.04	-1.26	-0.03	-1.83
XVIII	Earning Per Equity Share (for discontinued operation):					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):					
	1) Basic	0.48	0.04	-1.26	-0.03	-1.83
	2) Diluted	0.48	0.04	-1.26	-0.03	-1.83



For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited

(Signature)
Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063


Place : Delhi
Dated : 29/05/2022

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 March, 2022

	Particulars	Amount in INR	
		31.03.2022	31.03.2021
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit As Statement Profit & Loss	-42,08,275	-50,18,143
	Adjustment For		
	Discount received	-	-
	Non-Operating Income	-	-
	Interest Income	7,84,598	151
	Loss on sale of assets	-41,91,783	-
	Depreciation and Amortisation Expenses	8,40,873	18,92,123
	Operating Profit Before Change in Working Capital	-67,74,587	-31,25,869
	ADJUSTMENTS FOR WORKING CAPITAL:		
	Increase/Decrease in Loans and Advances	19,50,000	1,46,50,000
	Decrease/ (Increase) in Inventories	-	12,39,623
	Increase/Decrease in Security Deposits	-	1,50,000
	Increase/Decrease in Trade Receivables	6,49,119	3,77,573
	Increase/Decrease in Other Current Assets	-1,04,74,389	5,27,707
	Increase/Decrease in Current Liabilities	-66,45,124	10,28,228
	CASH GENERATED FROM OPERATIONS	-2,12,94,982	1,48,47,262
	Taxes Paid		
	Total (A)	-2,12,94,982	1,48,47,262
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	Additions/Sales to fixed assets	5,34,62,783	-1,57,93,000
	Purchase/Sell of Investments	-	-
	Discount received	-	-
	Non-Operating Income	-1,60,00,000	-
	Interest Income	-7,84,598	-151
	Total (B)	3,66,78,185	-1,57,93,151
C.	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from Borrowings	-1,54,70,944	6,82,867
	Preliminary Expenses	-	-
	Total (C)	-1,54,70,944	6,82,867
	NET CASH FLOWS DURING THE YEAR (A+B+C)	-87,741	-2,63,022
	Cash and Cash Equivalents (Opening Balance)	1,14,532	3,77,554
	Cash and Cash Equivalents (Closing Balance)	26,791	1,14,532

For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited


Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063



Place : Delhi
Dated : 29/05/2022

Statement of Asset and Liabilities as at 31.03.2022

Particulars	As at	
	31/03/2022	31/03/2021
	Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	1,75,46,488	5,85,87,239
Capital work in progress	-	48,79,339
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	90,00,000	1,09,50,000
Security Deposits	50,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	3,902	80,812
Other non current assets	-	-
Total Non-Current Assets	2,66,00,390	7,45,47,390
Current Assets		
Inventories	-	-
Financial Assets:	-	-
Investments	-	-
Trade Receivables	-	6,49,119
Cash and Cash equivalents	-	-
Other Balances with banks	26,791	1,14,532
Loans	-	-
Other financial assets	-	-
Other Current assets	1,13,47,043	8,72,654
Total Current Assets	1,13,73,835	16,36,305
Total Assets	3,79,74,225	7,61,83,694
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	3,05,45,000	3,05,45,000
Other Equity	-17,58,757	1,43,34,645
Total Equity	2,87,86,243	4,48,79,645
Non Current Liabilities		
Financial liabilities		
Borrowings	-	1,54,70,944
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	-	-
Provisions	-	-
Other Non Current liabilities	70,45,000	71,20,000
Total Non Current Liabilities	70,45,000	2,25,90,944
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	-	3,95,220
Other Financials liabilities	-	-
Provisions	1,45,426	1,29,834
Other Current liabilities	19,97,556	81,88,051
Total Current Liabilities	21,42,982	87,13,105
TOTAL EQUITY AND LIABILITIES	3,79,74,225	7,61,83,694

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 28, 2022 and concluded on May 29th 2022 the Statutory Auditors of the company have audited these financials results.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.
- The intangible asset namely "domain" will be ammortised over 4 years of useful life.

Bhambhani

For and on behalf of the Board of Directors
Genomic Valley Biotech Limited

Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063



Place : Delhi
Dated : 29/05/2022

ANDROS & CO.

CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

Independent Auditor's Report on the Financial Result of Genomic Valley Biotech Limited.

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Auditor's Report on the Audited Financial Results for the Quarter and year ended
March 31, 2022**

Opinion

We have audited the accompanying statement of financial results of Genomic Valley Biotech Limited ("the Company") for the quarter and year ended 31st March, 2022 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


- i. is presented in accordance with the requirements of regulation 33 the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the recognition and measurement Principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit/(loss) and other comprehensive income and other financial information of the Company for the quarter and year then ended 31st March, 2022.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the companies Act, 2013, ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results for the quarter and year ended 31st March, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The management of the Company is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/(loss) and other comprehensive income of the Company and other financial information in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with- relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for



safeguarding of the Assets of the Company and for preventing and detecting frauds and other Irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting Process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference financial statements in place and the operating effectiveness of such controls,
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management of the company.
- Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulation
- Conclude on the appropriateness of the board of director's use of going concern basis of accounting and, based on audit evidence obtained, whether the material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's reports to the related disclosures in the financial result or, If such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future event or condition may cause the Company, to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Result.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit,


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of the above matter.

**For ANDROS & CO.
Chartered Accountants**



**(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)**

UDIN: 22502310-AJVNZZ-4539

**Place: Delhi
Date: 29-05-2022**

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Beni Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



May 29, 2022

To
BSE Ltd.
P. J. Towers, Dala1 Street,
Mumbai – 400001
Scrip Code: 539206

Sub: Declaration on Audit Reports with an unmodified opinion

Dear Sir/ Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s ANDROS & CO., Chartered Accountants (Firm Registration No. 008976N), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the year ended March 31, 2022.

Kindly take the same on record.

Thanking you.

For Genomic Valley Biotech Limited


Yogesh Agrawal
Managing Director



Lalit Shah
Chief Financial Officer

Investor E-mail id: genomicvalley@gmail.com

ABOUT US

SBR & Co. LLP (SBRC) is an integrated service firm focused on corporate laws, registered as a Limited Liability Partnership under LLP ACT, 2008. SBRC is practicing company secretaries firm with the Institute of Company Secretaries of India (ICSI). SBRC is engaged in rendering efficacious services to its clients in the field of Company Law, Securities Laws, inbound and outbound Investment, Legal Due Diligence, Transaction documents, Joint Ventures, Foreign Collaborations, Technology Transfers, Mergers and Acquisitions, Listings and Capital Market Transactions.

SBRC key offerings also include setting up compliances, approvals from all the government departments including approvals from the Registrar of Companies, Ministry of Corporate Affairs, Foreign Investment Promotion Board (FIPB), Secretariat of Industrial Approvals (SIA), Reserve Bank of India (RBI), Director General of Foreign Trade (DGFT), Software Technology Parks of India (STPI), approvals for establishment of 100% Export Oriented Units (EOU), approvals for establishment of units in the Special Economic Zones (SEZ), Foreign Exchange Regulations, Foreign Direct Investment (FDI) in Retail, Trading, Non-banking finance companies etc.

Headquartered in Mumbai and having a branch in Gurugram and associates representing us in all the major cities of India, SBC has been in the forefront of the corporate sphere, having advised and represented corporate clients from across the globe, through a combination of hand holding and guidance. The partners have an average experience of over 10 years in handling complex legal issues touching on almost all aspects of Indian Corporate law. Team of 20 is working with SBC, out of which 8 are qualified professionals like CS/CA/LL.B.

OUR MISSION

SBRC strive to create a sustainable organization by developing a compliant environment by delivering qualitative, time bound & value-added services through optimum utilization of technology, professional skills and enduring customer satisfaction.

OUR VISION

SBRC is committed to be a leading one-stop solution partner with an edge in corporate governance and drive corporates to be 100% tech-compliant. Our vision serves as the route map of every aspect of our business by defining what we require to achieve for a sustainable and quality growth with substantial presence.

OUR AIMS

Our aim is to offer valuable insight into the prevailing economic and commercial climate of the country so as to promote a better understanding of the business and legal environment and assist clients in making decisions.

PARTNERS

Sumant K. Bhargava is founder partner of the firm. He has versatile exposure of more than 10 years in Corporate Laws and Compliances, FEMA, Registration and Licensing, Drafting and other legal matters. He has extensive knowledge and corporate experience.

Prior to entering into the profession of Practicing Company Secretary, he was employed as Company Secretary and Compliance Manager in various industries such as real estate, retail, media and logistics.

His major assignments in recent times include issue and listing of securities, XBRL, pre and post acquisition due diligence, closure of shareholders' agreement, JV/franchise/brand agreements, FEMA compliances, compounding of offences.

He has extensively traveled PAN India on professional engagements.

He has participated in the Board Leadership Training of Trainers Workshop conducted by International Financial Corporation, Global Corporate Governance Forum, NISM and ICSI.

He is a Fellow member of the Institute Company Secretaries of India and Bachelor of Commerce.

Rohit Batham associated with the profession of Company Secretaries for more than 8 years, is presently practicing as a Company Secretary and is the Founder Partner and branch head - Gurugram.

He had started his career as a company secretary of a renowned listed company. Later he entered in to profession of Practicing Company Secretary. He has versatile exposure in Corporate Laws and Accounting Compliances. He has hands on experience in Corporate Filings, dealing with statutory bodies, secretarial audit matters.

His major assignments in recent times include secretarial audit services, appearance before NCLT, Registrar of Companies, Buy back of shares, Condonation of delay, shifting of registered office, bulk XBRL, Handling Listed company compliances, etc.

He has extensively travelled PAN India on professional engagements.

He has participated in the Workshop conducted by IFCI and ICSI.

He is an Associate member of the Institute Company Secretaries of India, Bachelor of Law and Bachelor of Commerce.

MEET OUR TEAM

Jasneet Kaur Sahdev is a Company Secretary with 8 years of post-qualification experience in the field of Corporate Laws and Compliances, Bank Audits, FEMA, Taxation, Registration and Licensing, Project Financing from Banks and financial Institutions, Procurement of Export Licenses and other matters related to DGFT, Procurement of 100% EOU Licenses from Export Processing Zones (NEPZ), Drafting and other legal and financial matters mainly in to government companies.

Saurabh Gupta is a Chartered Accountant with 14 years of post-qualification experience in finance domain. He specializes in Strategic planning and Implementation, Finance & Accounts, Financial Control & Fund Management, Auditing & Statutory Compliances. He is having versatile corporate experience in Retail & FMCG Sector and has worked in financial controller role with DLF Brands.

Shivani Gupta is a Chartered Accountant with more than 7 years of post-qualification experience in statutory compliances, taxation and internal audit. Prior to associating with GSC, Shivani was employed in industry in Manager-Taxation role with a Listed EPC company.

Umakant Upadhyay is a Company Secretary from Institute of company secretary with experience of more than 3 years in experience on Corporate Law matters viz, Companies Act, Foreign Exchange Laws, IPR Laws, Corporate Secretarial, Incorporation of Companies, MCA 21 services, Secretarial Audit, XBRL & ROC searches Listing Agreements.

OUR SERVICES

- ❖ Registration, Registration, Formation & Incorporation of Private, Private, Public and Non-Profit Organization
- ❖ Formation of LLP (Limited Liability Partnership)
- ❖ Registration of Societies and Trusts Conversion
- ❖ Conversion of Private Company into Public and vice versa.
- ❖ Mergers, Amalgamations & Takeovers
- ❖ Listing and Delisting of Securities of Companies
- ❖ Secretarial Audit and Share Reconciliation Audit
- ❖ Corporate Governance Certification
- ❖ Annual Filing of Private, Public and Listed Companies
- ❖ Annual Filing or Balance sheet filing in XBRL Mode
- ❖ Certification of Depository Participants, Participants, Share Transfers, Managerial Remuneration, Annual Return etc.
- ❖ Consultation on All Corporate Laws & Tax Laws, GST Registration
- ❖ Expert advice on primary & Secondary Stock Market Appearance before NCLT, Registrar of Companies, Regional Director, Consumer Court & other Semi-Judicial Authorities.
- ❖ Buy back of shares
- ❖ Compounding of offences under Companies Act
- ❖ Condonation of Delay under Companies Act
- ❖ Shifting of Registered Office of the Company from one state to another
- ❖ Management Consultancy
- ❖ Project Financing
- ❖ Handling of all Secretarial, Financial and Legal functions of the Company


Private & Confidential

SBR & Co. LLP

Company Secretaries

- ❖ Arranging & Conducting Board and General Meetings of the Company and all other group Companies and subsequent follow up decisions thereof
- ❖ Liaison and interaction with Company Advocates, Solicitors and Legal Consultants
- ❖ Preparation, Execution and Registration of all Legal documents
- ❖ Liaison with Lead Manager, SEBI, Stock Exchange, Registrar of Companies, Reserve Bank of India, Ministry of Corporate Affairs and other Government authorities
- ❖ All works related to the Company's Trademarks and Copyrights. Appearing before Trademarks and Copyrights Registrar
- ❖ Statutory Certification
- ❖ Services to Banks / FIs
- ❖ Issue of search and status reports,
- ❖ Advising on loan documentation and stamp duty etc.,
- ❖ Opinion on various company law matters,
- ❖ Advising on creation and registration of charges.
- ❖ Compliance audits
- ❖ RBI and Forex Laws Compliance
- ❖ Setting up of Foreign Subsidiaries.
- ❖ Setting up of Branch office, Liaison office, Project office and related compliances.
- ❖ FDI (Foreign Direct Investment) compliances.
- ❖ NRI (Non-Resident Indian) investment and compliances.
- ❖ Setting up of Offshore Companies

LEADING CLIENTS



SBR & Co. LLP

Company Secretaries

For more information, reach us at:
SBR & CO. LLP, Company Secretaries

Head Office: Mumbai

G-44, Plot No. 47, Fantasia Business Park
Near Inorbit Mall, Sector-30A, Vashi, Navi Mumbai-400703
Handheld: +91 9873222067, Landline: +91 22 4974 2067

Branch Office: Gurugram

624C, Block H, Palam Vihar, Gurugram, Haryana – 122017
Handheld: +91 8010091909
Landline: +91 124 4206 012

Email Id. sbc@sbcoindia.com

Website: www.sumant.bhargava@sbcoindia.com